CSii has recently collaborated with ValenTx Inc. to test the safety and effectiveness of a novel intervention for bariatric treatment. ValenTx, Inc. has developed a revolutionary new therapy to treat patients with obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. The implantable Endoscopic Gastric Bypass Device is designed to mimic the therapeutic mechanisms of the Roux-en-Y gastric bypass procedure, with a non-surgical, endoluminal bypass device. The device is implanted by anchor attachment to the gastro- esophageal junction at the entrance to the stomach and to pass through the stomach and the first 100 cm of the small intestine. The device is implanted using endoscopy and is composed of a cuff, anchors, and a long detachable sleeve. The ValenTx Endo Bypass system provides a less invasive alternative to gastric bypass surgery. By providing restrictive and malabsorptive elements, the device should promote significant weight loss while reducing the negative impact of co-morbidities.
ValenTx is a medical device company focused on minimally invasive approaches for the treatment of morbid obesity. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy. The team is comprised of experienced medical device executives and collaborates extensively with leading scientists and physicians. CSii will participate in the Endo Bypass System clinical trial, as the first North American site. The Clinical Trial Agreement has been signed, and Research Ethics Approval and Health Canada Investigational Testing Approval have been obtained. CSii has been in collaboration with ValenTx to create study documents, develop study procedures and processes, and has a research staff prepared and excited to begin this innovative device trial.